CA Patent

CA2647543A1 — Inhibition of alpha-synuclein toxicity

Assigned to FoldRx Pharmaceuticals LLC · Expires 2007-11-08 · 19y expired

What this patent protects

Compounds and compositions are provided for treatment or amelioration of one or more symptoms of .alpha.-synuclein toxicity, .alpha.-synuclein mediated diseases or diseases in which .alpha.-synuclein fibrils are a symptom or cause of the disease.

USPTO Abstract

Compounds and compositions are provided for treatment or amelioration of one or more symptoms of .alpha.-synuclein toxicity, .alpha.-synuclein mediated diseases or diseases in which .alpha.-synuclein fibrils are a symptom or cause of the disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA2647543A1
Jurisdiction
CA
Classification
—
Expires
2007-11-08
Drug substance claim
No
Drug product claim
No
Assignee
FoldRx Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.